280 related articles for article (PubMed ID: 25533286)
1. IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5(+) B- and T-cell trafficking to tumor-conditioned media.
Pimenta EM; De S; Weiss R; Feng D; Hall K; Kilic S; Bhanot G; Ganesan S; Ran S; Barnes BJ
Immunol Cell Biol; 2015; 93(5):486-99. PubMed ID: 25533286
[TBL] [Abstract][Full Text] [Related]
2. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
3. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
4. RelA driven co-expression of CXCL13 and CXCR5 is governed by a multifaceted transcriptional program regulating breast cancer progression.
Biswas S; Roy Chowdhury S; Mandal G; Purohit S; Gupta A; Bhattacharyya A
Biochim Biophys Acta Mol Basis Dis; 2019 Feb; 1865(2):502-511. PubMed ID: 30553016
[TBL] [Abstract][Full Text] [Related]
5. CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis.
Biswas S; Sengupta S; Roy Chowdhury S; Jana S; Mandal G; Mandal PK; Saha N; Malhotra V; Gupta A; Kuprash DV; Bhattacharyya A
Breast Cancer Res Treat; 2014 Jan; 143(2):265-76. PubMed ID: 24337540
[TBL] [Abstract][Full Text] [Related]
6. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
[TBL] [Abstract][Full Text] [Related]
7. A conserved region within interferon regulatory factor 5 controls breast cancer cell migration through a cytoplasmic and transcription-independent mechanism.
Pimenta EM; Barnes BJ
Mol Cancer; 2015 Feb; 14(1):32. PubMed ID: 25649192
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome Network Analysis Identifies CXCL13-CXCR5 Signaling Modules in the Prostate Tumor Immune Microenvironment.
Ohandjo AQ; Liu Z; Dammer EB; Dill CD; Griffen TL; Carey KM; Hinton DE; Meller R; Lillard JW
Sci Rep; 2019 Oct; 9(1):14963. PubMed ID: 31628349
[TBL] [Abstract][Full Text] [Related]
9. IRF5: a rheostat for tumor-infiltrating lymphocyte trafficking in breast cancer?
Garaud S; Willard-Gallo K
Immunol Cell Biol; 2015; 93(5):425-6. PubMed ID: 26010613
[No Abstract] [Full Text] [Related]
10. CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking.
Wiener A; Schippers A; Wagner N; Tacke F; Ostendorf T; Honke N; Tenbrock K; Ohl K
Clin Exp Immunol; 2016 Jul; 185(1):22-32. PubMed ID: 26990531
[TBL] [Abstract][Full Text] [Related]
11. Spin90 deficiency increases CXCL13-mediated B cell migration.
Park SH; Kim HR; Jun CD; Song WK; Park SG
Scand J Immunol; 2014 Sep; 80(3):191-7. PubMed ID: 24965518
[TBL] [Abstract][Full Text] [Related]
12. CXCL13/CXCR5 signaling axis in cancer.
Hussain M; Adah D; Tariq M; Lu Y; Zhang J; Liu J
Life Sci; 2019 Jun; 227():175-186. PubMed ID: 31026453
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation of Single CpG Dinucleotides at the Promoter of CXCL13 Gene Promoting Cell Migration in Cervical Cancer.
Ma D; Fan SB; Hua N; Li GH; Chang Q; Liu X
Curr Cancer Drug Targets; 2020; 20(5):355-363. PubMed ID: 31899677
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection.
Cagigi A; Mowafi F; Phuong Dang LV; Tenner-Racz K; Atlas A; Grutzmeier S; Racz P; Chiodi F; Nilsson A
Blood; 2008 Dec; 112(12):4401-10. PubMed ID: 18780835
[TBL] [Abstract][Full Text] [Related]
15. CXCL13 inhibition induce the apoptosis of MDA-MB-231 breast cancer cells through blocking CXCR5/ERK signaling pathway.
Ma JJ; Jiang L; Tong DY; Ren YN; Sheng MF; Liu HC
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8755-8762. PubMed ID: 30575916
[TBL] [Abstract][Full Text] [Related]
16. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E
Brain; 2006 Jan; 129(Pt 1):200-11. PubMed ID: 16280350
[TBL] [Abstract][Full Text] [Related]
17. p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells.
Mitkin NA; Hook CD; Schwartz AM; Biswas S; Kochetkov DV; Muratova AM; Afanasyeva MA; Kravchenko JE; Bhattacharyya A; Kuprash DV
Sci Rep; 2015 Mar; 5():9330. PubMed ID: 25786345
[TBL] [Abstract][Full Text] [Related]
18. CXC chemokine ligand-13 promotes metastasis via CXCR5-dependent signaling pathway in non-small cell lung cancer.
Chao CC; Lee WF; Wang SW; Chen PC; Yamamoto A; Chang TM; Weng SL; Liu JF
J Cell Mol Med; 2021 Oct; 25(19):9128-9140. PubMed ID: 34427969
[TBL] [Abstract][Full Text] [Related]
19. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses.
Chevalier N; Jarrossay D; Ho E; Avery DT; Ma CS; Yu D; Sallusto F; Tangye SG; Mackay CR
J Immunol; 2011 May; 186(10):5556-68. PubMed ID: 21471443
[TBL] [Abstract][Full Text] [Related]
20. Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS.
Pranzatelli MR; Tate ED; McGee NR; Travelstead AL; Ransohoff RM; Ness JM; Colliver JA
J Neuroimmunol; 2012 Feb; 243(1-2):81-8. PubMed ID: 22264765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
